Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1384489 (
Scratch
)
395
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We investigated the effects of
aquaporin 5
(
AQP5
) gene silencing on the proliferation, migration and apoptosis of human glioma cells through regulating the EGFR/ERK/p38MAPK signaling pathway. qRT-PCR was applied to examine the mRNA expressions of
AQP5
in five human glioma cell lines. U87-MG, U251 and LN229 cells were selected and assigned into blank, vector,
AQP5
siRNA and FlagAQP5 groups. MTT assay was used to measure cell proliferation. Flow cytometry (FCM) with AnnexinV-FITC/PI double staining and PI staining were employed to analyze cell apoptosis and cell cycle respectively.
Scratch
test was used to detect cell migration. Western blotting was performed to determine the EGFR/ERK/p38 MAPK signaling pathway-related proteins. Results showed that the positive expression of
AQP5
in primary glioblastoma was associated with the tumor size and whether complete excision was performed. The mRNA expressions of
AQP5
in cell lines of U87-MG, U251 and LN229 were significantly higher than in U373 and T98G. The proliferation rates of U87-MG, U251 and LN229 cells in the
AQP5
siRNA group were lower than in the vector and blank groups. The apoptosis rate increased in the
AQP5
siRNA group compared with the vector group.
Scratch
test demonstrated that
AQP5
gene silencing could suppress cell migration. Compared with the vector and blank groups, the
AQP5
siRNA group showed decreased expressions of the ERK1/2, p38 MAPK, p-ERK1/2 and p-p38 MAPK proteins.
AQP5
gene silencing could inhibit the cell proliferation, reduce cell migration and promote the cell apoptosis of U87-MG, U251 and LN229 by suppressing EGFR/ERK/p38 MAPK signaling pathway.
...
PMID:Effects of AQP5 gene silencing on proliferation, migration and apoptosis of human glioma cells through regulating EGFR/ERK/ p38 MAPK signaling pathway. 2840 78